Skip to content

Prospective randomized controlled clinical study on the efficacy and safety of salmon liquid calcium in the treatment of osteoporosis

Prospective randomized controlled clinical study on the efficacy and safety of salmon liquid calcium in the treatment of osteoporosis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500104591
Enrollment
Unknown
Registered
2025-06-19
Start date
2025-07-01
Completion date
Unknown
Last updated
2025-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoporosis

Interventions

Control group:Take calcium carbonate tablets (Caltech)
Intervention group:Taking salmon liquid calcium

Sponsors

Zhongshan Hospital, Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. 50-80 years old; 2. Diagnosed as primary osteoporosis or bone loss (bone density measurement, -2.5<T value<-1.0); 3. The subjects are able to cooperate with intervention, investigation, and follow-up, with clear consciousness and high cooperation; 4. Has not suffered from any known immunodeficiency diseases, metabolic disorders, or digestive abnormalities, such as hypothyroidism, renal dysfunction, gastrointestinal dysfunction, etc; 5. Not taking any medication known to affect bone mineral metabolism recently (such as hormones, diuretics, or antiepileptic drugs, etc.); 6. Not participating in other clinical trials.

Exclusion criteria

Exclusion criteria: 1. Patients with severe osteoporosis who have not shown significant improvement or progression after standardized anti osteoporosis treatment in the past; 2. Liver and kidney dysfunction, or previous severe urinary system stones; 3. Combination of important organ dysfunction and inability to take oral calcium supplements; 4. Researchers believe that subjects who are not suitable for this clinical practice; 5. Individuals with combined mental illnesses or unable to cooperate with corresponding diagnosis and treatment follow-up.

Design outcomes

Primary

MeasureTime frame
Adverse reaction rate;

Secondary

MeasureTime frame
Rate of bone mineral density remission;Subjective symptom remission rate;

Countries

China

Contacts

Public ContactHuiren Wang

Zhongshan Hospital, Fudan University

wang.huiren@zs-hospital.sh.cn+86 137 8899 9017

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026